美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CAR-T

1,707.29

-7.9861-0.47%

漲家數：- -

跌家數：2

平家數：- -

市盈率：- -

高：1,738.14

開：1,723.93

低：1,706.26

收：1,715.28

成交量：672.09萬

成交額：9.52億

市值：4,400.12億

流通市值：4,318.32億

資料載入中...

通用電氣維諾華公司：與愛爾蘭國家電力公司達成協議，將為蘇格蘭高地的96兆瓦奇倫塞德風電場供應16台6.1兆瓦-158米型

諾華公司：計劃停止克萊因巴塞爾生產基地的生產可能導致約130個工作崗位流失。所有計劃中的變更均需經過信息告知與協商程序。

諾華集團：高效口服BTK抑制劑瑞米布替尼在III期RMS臨床試驗中顯著降低複發率安全性表現良好

諾華製藥（NVS）漲6% 在BTK抑制劑賽道迎來重要突破

美股異動 | 諾華製藥升逾5%，MS口服藥後期試驗告捷

諾華製藥(NVS)股票9月1日盤中上漲6.54%：真相來了

TradingKey中文

諾華製藥(NVS.US)神經免疫管線「悲喜交加」：患者死亡致CAR-T臨床試驗暫停 MS口服藥後期試驗告捷

諾華暫停該項目，此前已報告3起嚴重的免疫效應細胞相關噬血細胞綜合徵病例，併發症最終導致患者死亡。

諾華：出現死亡病例，暫停自身免疫細胞療法相關研究

邦順製藥赴港IPO，創始團隊出自華東醫藥，面臨諾華、澤璟製藥的競爭

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK4578/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T","latestPrice":1707.2908,"timestamp":1789156799999,"preClose":1715.2769,"halted":0,"volume":6720884,"delay":0,"changeRate":-0.004656,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-7.986084,"latestTime":"09-11 16:00:00 EDT","open":1723.9307,"high":1738.1443,"low":1706.258,"amount":952105821.827941,"amplitude":0.01859,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.281713,"peRate":46.44356,"turnoverRate":0.002176,"increases":0,"decrements":2,"flats":0,"marketCap":440011767808,"floatMarketCap":431831957504},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1738.1443,"amplitude":0.01859,"preClose":1715.2769,"low":1706.258,"pbRate":"8.281713","latestPrice":1707.2908,"volume":6720884,"delay":0,"open":1723.9307,"prevYearClose":1612.5378,"prevWeekClose":1911.2454,"prevMonthClose":1830.2803,"prevQuarterClose":1768.1697,"fiveDayClose":1934.9851,"twentyDayClose":1787.5502,"sixtyDayClose":1729.702,"secType":"PLATE","market":"US","turnoverRate":0.002176,"peRate":46.44356,"marketCap":440011767808,"floatMarketCap":431831957504,"timestamp":1789156799999,"nameCN":"CAR-T"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":0,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664694879","title":"通用電氣維諾華公司：與愛爾蘭國家電力公司達成協議，將為蘇格蘭高地的96兆瓦奇倫塞德風電場供應16台6.1兆瓦-158米型","url":"https://stock-news.laohu8.com/highlight/detail?id=2664694879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664694879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 19:17","pubTimestamp":1788434237,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BJJMRZ35.SGD","BK4585","BK4532","PPH","IE00B4R5TH58.HKD","LU0211331839.USD","IE0009355771.USD","LU0070302665.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","NVS","BK4578","IE00BJT1NW94.SGD","IE0002141913.USD","LU0208291251.USD","BK4588","IE00B2B36J28.USD","BK4007","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811784","title":"諾華公司：計劃停止克萊因巴塞爾生產基地的生產可能導致約130個工作崗位流失。所有計劃中的變更均需經過信息告知與協商程序。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811784","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811784?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:37","pubTimestamp":1788352638,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BJT1NW94.SGD","IE0002141913.USD","LU0208291251.USD","PPH","BK4578","BK4588","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","HELS","LU0211331839.USD","LU0320765489.SGD","NVS","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4585","IE00B4R5TH58.HKD","BK4532","BK4007","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815045","title":"諾華集團：高效口服BTK抑制劑瑞米布替尼在III期RMS臨床試驗中顯著降低複發率 安全性表現良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815045","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815045?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:11","pubTimestamp":1788347485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765489.SGD","IE00B2B36J28.USD","BK4532","BK4007","LU0208291251.USD","IE00BFTCPJ56.SGD","MDTX","IE0002141913.USD","IBBJ","BK4588","NVS","MEDX","PSYK","IE00BJJMRZ35.SGD","LU0211331839.USD","PPH","LU0070302665.USD","BK4578","IBBQ","IE00BJT1NW94.SGD","BMED","IE0009355771.USD","BK4585","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664850928","title":"諾華製藥（NVS）漲6% 在BTK抑制劑賽道迎來重要突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2664850928","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664850928?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 23:18","pubTimestamp":1788275914,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华制药 早盘股价扬升，最新涨6%，报161.2美元，成交额3.2亿美元。诺华周二公布，对比对照药物特立氟胺，瑞米布替尼可降低患者疾病复发率，减少脑部病灶数量，试验中未观察到肝脏相关安全风险。该药有望成为诺华重磅产品Kesimpta的后续迭代品种，同时印证BTK抑制剂在抑制异常免疫反应方面的治疗潜力。诺华计划向全球监管机构提交瑞米布替尼治疗多发性硬化症的上市申请，完整临床数据将于今年晚些时候在多伦多医学会议对外披露。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/YmFmZjgzNDhkMjgxZmE5MWVmYzk4MzgzNTg2ODExODg1NTU0MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YmFmZjgzNDhkMjgxZmE5MWVmYzk4MzgzNTg2ODExODg1NTU0MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305587","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","BK4585","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","BK4588","LU0070302665.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","BK4007","BK1191","BK1574","IE00B2B36J28.USD","BK4578","BK4532","PPH","MEDX","IE0009355771.USD","01477","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664016854","title":"美股異動 | 諾華製藥升逾5%，MS口服藥後期試驗告捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664016854","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664016854?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:35","pubTimestamp":1788273301,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，诺华制药涨逾5%，报160.82美元。消息面上，诺华表示，试验显示，接受瑞米布替尼治疗的患者与接受特立氟胺治疗的患者相比，复发率和脑部病变数量均有所减少，且未观察到肝脏安全信号。该药有望为诺华提供一种治疗多发性硬化症的新型口服药物，并成为其重磅产品Kesimpta系列的后续产品。此前，赛诺菲和默克公司的类似药物在后期试验中未能在复发率指标上优于特立氟胺。","market":"fut","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490652.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺华制药MS口服药后期试验告捷","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IE0009355771.USD","LU0211331839.USD","BK4532","BK4578","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0070302665.USD","NVS","LU0320765489.SGD","BK1574","PPH","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","MEDX","BK4007","BK4585","LU0208291251.USD","IE0002141913.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664524478","title":"諾華製藥(NVS)股票9月1日盤中上漲6.54%：真相來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2664524478","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664524478?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:16","pubTimestamp":1788272176,"startTime":"0","endTime":"0","summary":"• Remibrutinib 在三期多发性硬化症试验中取得成功，展现出临床优效性。\n• 在三名患者死亡后，诺华暂停了八项早期 CAR-T 试验。\n• 该公司报告年收入为 563.3 亿美元，净利润为 139.8 亿美元。","market":"fut","thumbnail":"https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262144173-market-movers-nvs-20260901","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","IE00BFTCPJ56.SGD","MEDX","LU0320765489.SGD","BK4585","LU0070302665.USD","BK4007","BK4532","IE00BJJMRZ35.SGD","BK4588","BK1191","LU0208291251.USD","NVS","IE0009355771.USD","IE00BJT1NW94.SGD","LU0211331839.USD","IE0002141913.USD","IE00B4R5TH58.HKD","BK4578","IE00B2B36J28.USD","BK1574","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831619","title":"諾華製藥(NVS.US)神經免疫管線「悲喜交加」：患者死亡致CAR-T臨床試驗暫停 MS口服藥後期試驗告捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831619","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831619?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 15:40","pubTimestamp":1788248407,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药在神经与自身免疫领域迎来“冰火两重天”：公司因三名患者死亡紧急叫停八项CAR-T疗法临床试验;不过，其多发性硬化症口服药remibrutinib在后期临床试验中取得积极结果。CAR-T试验紧急暂停诺华制药在8月底暂停了八项针对自身免疫和神经系统疾病的实验性疗法临床试验，此前有三名患者死亡。诺华制药发言人表示，公司正在“对所观察到的安全事件进行全面审查”，并将这种致命免疫反应描述为CAR-T疗法中已知的安全风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4578","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4585","IE0002141913.USD","BMED","MEDX","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4007","BK1574","LU0208291251.USD","NVS","IBBJ","01477","PPH","IE00B2B36J28.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","IBBQ","BK4588","LU0070302665.USD","MDTX","BK4532","PSYK","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664839602","title":"諾華暫停該項目，此前已報告3起嚴重的免疫效應細胞相關噬血細胞綜合徵病例，併發症最終導致患者死亡。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664839602","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664839602?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 15:23","pubTimestamp":1788247409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765489.SGD","IE00B2B36J28.USD","BK4532","BK4007","LU0208291251.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4588","NVS","MEDX","IE00BJJMRZ35.SGD","LU0211331839.USD","PPH","LU0070302665.USD","BK4578","IE00BJT1NW94.SGD","IE0009355771.USD","BK4585","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800188","title":"諾華：出現死亡病例，暫停自身免疫細胞療法相關研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664800188?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 12:21","pubTimestamp":1788236460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765489.SGD","IE00B2B36J28.USD","BK4532","BK4007","LU0208291251.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","CNCR","BK4588","NVS","MEDX","SYNB","IE00BJJMRZ35.SGD","LU0211331839.USD","WDNA","PPH","LU0070302665.USD","BK4578","IE00BJT1NW94.SGD","IE0009355771.USD","BK4585","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882712","title":"邦順製藥赴港IPO，創始團隊出自華東醫藥，面臨諾華、澤璟製藥的競爭","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882712","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664882712?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 10:21","pubTimestamp":1788229285,"startTime":"0","endTime":"0","summary":"两年半累计亏损4.67亿","market":"hk","thumbnail":"https://img2.gelonghui.com/bf122-cc396b77-81ef-4c91-ae6d-db59d48043ce.jpg?guru_height=909&guru_width=1473&guru_size=100893","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/bf122-cc396b77-81ef-4c91-ae6d-db59d48043ce.jpg?guru_height=909&guru_width=1473&guru_size=100893"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6439376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["IE00BJJMRZ35.SGD","BK4585","BK4532","BK0196","IE00B4R5TH58.HKD","LU1969619763.USD","LU0211331839.USD","BK0175","IE0009355771.USD","PPH","BK0209","BK4127","KCE","BK0183","LU0070302665.USD","LU0320765489.SGD","BK1574","BK1191","IE00BFTCPJ56.SGD","NVS","BK4578","IPOS","LU2328871848.SGD","IE00BJT1NW94.SGD","REDS","BK0132","IE0002141913.USD","BK0188","FRHC","BK0187","LU0208291251.USD","BK4588","IE00B2B36J28.USD","BK4007","01477","000963","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":50,"code":"91000000","status":"200"}]}}